Last reviewed · How we verify
Clareon PanOptix PRO
Clareon PanOptix PRO is a Small molecule drug developed by Berkeley Eye Center. It is currently FDA-approved for Cataract surgery with presbyopia correction (distance, intermediate, and near vision).
Clareon PanOptix PRO is a trifocal intraocular lens that provides simultaneous vision at multiple focal distances through diffractive optics.
Clareon PanOptix PRO is a trifocal intraocular lens that provides simultaneous vision at multiple focal distances through diffractive optics. Used for Cataract surgery with presbyopia correction (distance, intermediate, and near vision).
At a glance
| Generic name | Clareon PanOptix PRO |
|---|---|
| Sponsor | Berkeley Eye Center |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This intraocular lens uses advanced diffractive technology to split incoming light into three focal points—distance, intermediate, and near vision—allowing patients to see clearly across a range of distances without glasses. The lens is implanted during cataract surgery to replace the natural lens and restore functional vision at all distances.
Approved indications
- Cataract surgery with presbyopia correction (distance, intermediate, and near vision)
Common side effects
- Glare or halos around lights
- Reduced contrast sensitivity
- Posterior capsular opacification
Key clinical trials
- Clareon PanOptix Pro vs. Clareon PanOptix - Study B (NA)
- Clareon PanOptix Pro vs. Clareon PanOptix - Study A (NA)
- Outcomes of Clareon PanOptix Pro in Patients With Prior Myopic Refractive Surgery
- Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs (NA)
- Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro (NA)
- A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clareon PanOptix PRO CI brief — competitive landscape report
- Clareon PanOptix PRO updates RSS · CI watch RSS
- Berkeley Eye Center portfolio CI
Frequently asked questions about Clareon PanOptix PRO
What is Clareon PanOptix PRO?
How does Clareon PanOptix PRO work?
What is Clareon PanOptix PRO used for?
Who makes Clareon PanOptix PRO?
What development phase is Clareon PanOptix PRO in?
What are the side effects of Clareon PanOptix PRO?
Related
- Manufacturer: Berkeley Eye Center — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Cataract surgery with presbyopia correction (distance, intermediate, and near vision)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing